Cutaneous Toxicity as a Predictive Biomarker for Clinical Outcome in Patients Receiving Anticancer Therapy

The article discussed the potential of cutaneous toxicity as a predictive biomarker for clinical outcomes in patients undergoing anticancer therapy. It reviewed the association between skin toxicities caused by molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics, and the survival benefits observed in patients. Preliminary studies suggested a promising link, but larger prospective studies were needed to confirm this relationship. The article emphasized the importance of dermatologists collaborating with oncologists to manage these dermatologic events, which could help in recognizing the efficacy of anticancer treatments and influence treatment decisions and patient outcomes.